Rawan G. Faramand, Frederick L. Locke. "Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL." Nature Reviews Clinical Oncology (2025). https://doi.org/10.1038/s41571-025-00993-4